Memphasys keeps its Middle East push on track as new orders land and market expansion gathers pace

Memphasys (ASX: MEM) has lobbed a reassuring update into a jittery geopolitical backdrop, telling investors its Middle East and North Africa (MENA) push is not only intact, but quietly gathering pace.

In a market where “unaffected by regional conflict” is doing a lot of heavy lifting, the reproductive biotech minnow has delivered a rare combination: operational continuity, fresh orders and a pipeline of near-term market entries. Not bad for a company still early in its commercial rollout.

At the centre of the story is Memphasys’ flagship Felix™ System, a sperm selection technology targeting the global IVF market. While still a niche player, the company is clearly intent on building a recurring revenue model - one cartridge at a time.

Qatar: the anchor tenant

The company’s update leans heavily on Qatar, where Hamad Medical Corporation continues to use Felix in routine assisted reproductive procedures. This is more than just a proof-of-concept site - it’s the closest thing Memphasys has to a “set-and-forget” revenue stream.

Ongoing cartridge consumption is the key metric here. Unlike one-off capital equipment sales, the consumables model is where margins - and investor attention - tend to build over time. Memphasys notes that usage remains consistent, reinforcing the idea that Felix is becoming embedded in clinical workflows rather than sitting on the shelf.

In biotech parlance, that’s the difference between adoption and experimentation.

New orders: UAE and Iraq join the party

Beyond Qatar, Memphasys has secured new commercial orders from the United Arab Emirates and Iraq. While described as “initial in nature”, these orders matter less for their size and more for what they signal: geographic diversification.

For a small-cap medtech, reliance on a single market can be a fatal flaw. Memphasys appears acutely aware of this, highlighting that demand is emerging across multiple jurisdictions rather than clustering in one hotspot.

This scattergun approach may lack the glamour of a blockbuster contract, but it builds resilience - particularly in a region not exactly known for its geopolitical stability.

Egypt and Turkey: the next dominoes

The more interesting forward-looking elements sit in Egypt and Turkey, both flagged as near-term growth markets.

Egypt, in particular, stands out. Management describes it as one of the largest and fastest-growing IVF markets in the MENA region, and early signs of interest - following conference exposure in Cairo - suggest fertile ground. Regulatory processes are progressing, with trial orders expected next quarter.

Turkey follows a similar script: regulatory approvals underway, first commercial orders pencilled in for the next quarter.

Seasoned ASX watchers will know that “expected next quarter” can be an elastic concept, especially when regulatory bodies are involved. Still, the fact that both markets are tracking without reported delays is a positive signal in itself.

Supply chain: no news is good news

Perhaps the most understated - but critical - part of the update is the supply chain commentary.

Memphasys says logistics remain fully operational, with no delivery delays and the ability to ship directly into all contracted markets.

That might sound mundane, but against a backdrop of regional instability, it’s a key risk mitigant. The company’s partnership with International Technical Legacy (ITL) appears to be doing the heavy lifting here, providing both distribution reach and flexibility.

In short, the pipes are working - and for now, nothing is clogging them.

Strategy: slow burn, not a land grab

What emerges from this update is a company deliberately playing the long game.

Rather than relying on distributor-led bulk sales, Memphasys is focusing on clinic-level engagement - effectively building demand from the ground up. It’s a slower path, but one that aligns with its recurring revenue ambitions.

Chair of the Commercialisation Committee Marjan Mikel summed it up neatly, pointing to a model designed to “build demand at the clinic level across multiple markets,” with diversification acting as a buffer against regional shocks.

It’s a pragmatic approach. In a fragmented healthcare landscape like MENA, a one-size-fits-all rollout rarely works.

The bigger picture

For all the positive momentum, investors should keep expectations grounded. Memphasys is still in the early innings of commercialisation, and while order flow is encouraging, scale remains the ultimate prize.

The real test will be whether these early footholds translate into meaningful, repeatable revenue growth over the next 12–24 months.

That said, this update does tick several important boxes: operational resilience, expanding market footprint, and early signs of recurring demand.

In a sector where many stories stall at the regulatory hurdle or fade after initial hype, Memphasys is - quietly - doing the blocking and tackling.

Not headline-grabbing stuff, perhaps. But in biotech, progress often looks exactly like this.